122 results about "Alkaloid synthesis" patented technology

This invention provides compositions, methods and process of producing extracts and pure compounds from Xanthoceras sorbifolia. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder. This invention provides compounds of oleanene triterpenoidal saponin in nature with the characteristics that at least one angeloyl group attache to Carbon 21 or / and 22, or / and linked to the sugar. The compounds of the present invention have various pharmaceutical and therapeutic applications.

The present invention provides a composition of transdermally administered alkaloids from aconitum plant for ameliorating pain and inflammation. In one aspect, an aconitum alkaloid is delivered in a sufficient amount to achieve and maintain a blood plasma aconitum alkaloid level of about 0.5 ng / mL to about 400 ng / mL. Aconitum alkaloids may be delivered by themselves, or in combination with other elements, such as additional analgesics, other drugs, or positive health promoting substances. Various formulations for the transdermal delivery of aconitum alkaloids are disclosed, and may include selected penetration enhancers.

Aspects of the invention include host cells that are engineered to produce benzylisoquinoline alkaloids (BIAs). The host cells include heterologous coding sequences for a variety of enzymes involved in synthetic pathways from starting compounds to BIAs of the host cell. Also provided are methods of producing the BIAs of interest by culturing the host cells under culture conditions that promote expression of enzymes encoded by the heterologous coding sequences of the host cells. Aspects of the invention further include compositions, e.g., host cells, starting compounds and kits, etc., that find use in methods of the invention.

Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in Nicotiana plants and plant parts thereof are provided. The compositions comprise isolated polynucleotides and polypeptides for cytochrome P450s that are involved in the metabolic conversion of nicotine to nornicotine in these plants. Expression cassettes, vectors, plants, and plant parts thereof comprising inhibitory sequences that target expression or function of the disclosed cytochrome P450 polypeptides are also provided. Methods for the use of these novel sequences to inhibit expression or function of cytochrome P450 polypeptides involved in this metabolic conversion are also provided. The methods find use in the production of tobacco products that have reduced levels of nornicotine and its carcinogenic metabolite, NNN, and thus reduced carcinogenic potential for individuals consuming these tobacco products or exposed to secondary smoke derived from these products.

The present invention is directed to novel compositions of bio-active compounds comprising 4-hydroxyisoleucine and one or more compounds selected from the group of amino acids, alkaloids, glycosides, volatile oils, saponins, sapogenins, mannans, flavonoids, fatty acids, vitamins and provitamins, minerals, and carbohydrates. Preferably, the novel compositions of bio-active compounds include 4-hydroxyisoleucine and one or more amino acids selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, proline, lysine, histidine, and gamma-aminobutyrate. The composition of bio-active compounds preferably include between about ten percent and about seventy percent of 4-hydroxyisoleucine and between about twenty percent and about forty percent of other amino acids. The bio-active compounds of the novel composition of the present invention may be derived, isolated, and / or extracted from Fenugreek seeds. A preferred method for extracting the bio-active compounds from Fenugreek seeds includes the steps of: (1) providing a plurality of Fenugreek seeds; (2) preparing the Fenugreek seeds; and (3) extracting a novel composition of bio-active compounds from the Fenugreek seeds, which include a preliminary extraction step and a secondary extraction step. The compositions of bio-active compounds have been found to be helpful in restoring healthy energy balance in humans and animals, aiding in weight management efforts, and for balancing blood sugar levels by way of assisting the body to make more efficient use of existing (i.e., endogenous) insulin.

This invention provides compositions, methods and process of producing extracts from Xanthoceras sorbifolia. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for treating cancer, arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder, impotence and premature ejaculation; for preventing cerebral aging; for improving memory, cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's disease or other diseases caused by cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder. This invention provides compounds comprising at least one sugar, a triterpene, such as Sapogenin, and at least one side chains at Carbon 21 and 22, such as Angeloyl groups. The compounds of the present have various pharmaceutical and therapeutic applications.

There is provided an alkaloid formulation comprising the reaction product of one or more alkaloids with one or more phosphate derivatives of one or more electron transfer agents.

The present invention provides a method of treatment or management of various adaptogenic conditions, such as, stress in mammals, more particularly, humans, comprising administering Withania somnifera plant extract. A high purity extract composition comprising withanolide glycosides, oligosaccharides, withanolide aglycones and a minimum level of polysaccharides, and a pharmaceutically, veterinary or nutritionally acceptable carrier(s) is disclosed. Preferably, the composition of the present invention can be devoid of any alkaloids or contains trace levels of alkaloids. The method of treatment or management of stress administering the composition comprising Withania somnifera of the present invention does not suffer from any one of the abovementioned side effects even after prolonged use. A method of preconditioning a mammalian patient to improve the patient's resistance and reaction to subsequently encountered stress is described.

The present invention relates to a method for treating biological organic tissue, particularly plant tissue, by applying a direct current preferably of low voltage electrical field for short duration, with minimal detrimental influence on the treated tissue and to further beneficial uses of the residual tissue mass. The system and methods are useful for extraction and separation of substances of interest from the biological tissue, with optional concomitant reduction in enzyme activity, resulting in delayed or arrested browning of the tissue, and for production of imprint marks on the treated tissue. The present invention further relates to substances including pigments, minerals, oils, fragrances, vitamins, amino acids, alkaloids, extracted using the direct current treatment system, and to apparatus for performing the treatment.

The present invention provides novel methods of preventing and treating prostate cancer with tetrandrine, a bisphehol-isoquinoline alkaloid isolated from the Chinese herb Stephania tetrandra. The present invention also provides the use of tetrandrine for the manufacture of a pharmaceutical composition for treating prostate cancer. The tetrandrine can be used as any isomer of tetrandrine such as the (R,R), (S,S), (R,S), and (S,R) isomers and any combination of these isomers. The present invention also provides methods of inhibiting the growth of prostate cancer cells in vitro by contacting the cells with tetrandrine. The present invention also provides methods of inducing apoptosis in prostate cancer cells in vitro by contacting the cells with tetrandrine.

The present invention relates to methods and compositions comprising Areca catechu extracts and Piper betel extracts. Compositions comprise Areca catechu extracts that comprise alkaloid compounds in ratios that are different from the ratios found in native Areca plant material. Methods of the present invention comprise extractions of Areca catechu and Piper betel, making the compositions comprising Areca catechu and Piper betel and methods of providing compositions that mimic the effects in humans of chewing betel quid and have reduced carcinogenicity.

The invention discloses a planting method of fresh motherwort which comprises eight steps of seed selecting, seed processing, land selecting, land scraping, sowing, seed thinning, weeding, fertilizing and harvesting. By adopting modern agricultural techniques, the invention changes motherwort planting methods, improves wild motherwort species by adopting out-of-season cultivation, implements reasonable fertilization of chemical fertilizer and organic fertilizer, cultivates high-class fresh motherwort which is characterized by non-pollution, low residue of agricultural chemical and heavy metal, high yield, high efficiency and high biological activity by perfect tending, ensures the stability and the consistency of fresh motherwort quality, and improves the production yield and the medicine quality of motherwort. The total content of alkaloid in the fresh motherwort which is planted by the planting method of the invention reaches 2 percent, which is much higher than the dry motherwort (with the content of 0.4 percent) in traditional marketing.

The invention relates to quinoline compound, a synthesis method and the application for preparing medicines of camptothecin alkaloid. The syntheticroute is concise, high-efficient and economical, and can play a great role in promoting the later industrialized production of camptothecin alkaloid.

An apparatus and method for separating at least one narcotic alkaloid that includes loading a stationary phase media into a high performance preparative liquid chromatography column, feeding a crude narcotic alkaloid solution into the chromatographic column, applying a mobile phase to the chromatographic column, and recovering a narcotic alkaloid eluate from the chromatographic column. The narcotic eluates are collected and treated separately from each other. Each separated alkaloid, however, has sufficient recovery and purity.

The synthetic production of cis-1,4-polyisoprene and other cis-1,4-polydienes is achieved by adding isoprene or other diene monomers to a natural rubber latex or washed rubber particles and utilizing various allylic pyrophosphate compounds. The natural rubber latex or washed rubber particles inherently contain an enzyme catalyst and desirably divalent metal cofactors therein and the polymerization can occur over a relatively wide temperature range. The process is believed to be a living carbocationic polymerization. The in vitro produced natural rubber polymers can contain from about 5 to about 30,000 repeat units and are essentially free of non-enzyme catalysts. The invention can be utilized to synthesize polyisoprenoids and precursors to form terpenes, vitamins, steroids, alkaloids, and the like.

The invention relates to medical devices, compositions and methods useful for administrating or delivering a cephalotaxine to a host. The cephalotaxines are useful in treating or preventing an angiogenic condition or disease. The invention provides for medical devices including coatings containing a matrix and a cephtalotaxine to treat an angiogenic condition or disease. The invention provides for methods and compositions, including cephalotaxine alkaloids as antiangiogenic agents, for treatment of a host with an angiogenic condition or disease or for prophylactic treatment of a host to inhibit the onset or progression of an angiogenic condition or disease. The invention also provides for medical devices useful for delivering or administrating a cephalotaxine in vivo.

The present invention relates to a combination of a Neotyphodium species endophyte or endophyte culture in a symbiotic association with a host grass which association does not cause symptoms of toxicosis in animals through exclusion of ergovaline but, due to the inclusion of alkaloids including agroclavine, setoclavine or isosetoclavine, retains the ability to resist abiotic stresses and protect the grass from pests.

An Aids and associated conditions related to Aids treating compositions is disclosed. The compositions comprise: a medicament selected from an extract of at least one of the following plant families: Apocynaceae (Pleioscarpa Bicarpellata); Annonaceae (Cleistopholis Patens); Dichapetalaceae (Dichapetehan Madagasca Riense); Annoceae (Uvaristrum Pierreanum); Cynocynaceae (Strophantus Gratus); Asclepiadaceae (Gongronema Latifolium); Combretaceae (Combretum Racemosum); Apocynaceae (Alostonia Boonei); Amaranthaceae (Altemanthera Pungens); Aroceae (Anchomanes Differmis); Cyperaceae (Seleria Voivinil); Anacardiaceae (Lannea Acida); Bignoniaceae (Kigelia Africana); Bombacaceae (Ceiba Pentanota); Anarcardiaceae (Antrocaryon Micraster); Bombacaceae (Bombax Bounopozense): Anarcardiaceae (Spondias Mombin); Caricaceae (Carica Papaya); a glyceryl ester of any of the foregoing extracts; a saponin of any of the foregoing extracts; an alkaloid of any of the foregoing extracts; a protein of any of the foregoing extracts; a fat of any of the foregoing extracts; a sugar of any of the foregoing extracts; and any mixture of any of the foregoing.

The present invention is directed to novel compositions of bio-active compounds comprising 4-hydroxyisoleucine and one or more compounds selected from the group of amino acids, alkaloids, glycosides, volatile oils, saponins, sapogenins, mannans, flavonoids, fatty acids, vitamins and provitamins, minerals, and carbohydrates. Preferably, the novel compositions of bio-active compounds include 4-hydroxyisoleucine and one or more amino acids selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, proline, lysine, histidine, and gamma-aminobutyrate. The composition of bio-active compounds preferably include between about ten percent and about seventy percent of 4-hydroxyisoleucine and between about twenty percent and about forty percent of other amino acids. The bio-active compounds of the novel composition of the present invention may be derived, isolated, and / or extracted from Fenugreek seeds. A preferred method for extracting the bio-active compounds from Fenugreek seeds includes the steps of: (1) providing a plurality of Fenugreek seeds; (2) preparing the Fenugreek seeds; and (3) extracting a novel composition of bio-active compounds from the Fenugreek seeds, which include a preliminary extraction step and a secondary extraction step. The compositions of bio-active compounds have been found to be helpful in restoring healthy energy balance in humans and animals, aiding in weight management efforts, and for balancing blood sugar levels by way of assisting the body to make more efficient use of existing (i.e., endogenous) insulin.

Ergot alkaloids are isolated from ergot in high yields and purity by a process including extracting Claviceps purpurea, i.e., ergot, with a toluene / ethanol solvent mixture to obtain a primary extract. The primary extract can be further subjected to two steps of liquid-liquid extraction to purify the alkaloids resulting in a purified toluene extract. The toluene extract can be further partially evaporated and a crystalline product obtained by crystallization from the toluene or a mixture of toluene and an aliphatic hydrocarbon.

The invention discloses application of a transcription factor involved in regulating tomato steroid alkaloid synthesis. The amino acid sequence of the transcription factor SlbHLH114 is as shown in SEQID NO.4, and the nucleotide sequence is as shown in SEQ ID NO.3. Overexpression of the transcription factor has a positive regulating effect on the synthesis of tomato steroid alkaloids, so the steroid alkaloid content of transgenic lines can be improved by overexpressing the transcription factor SlbHLH114 in plants, and a theoretical basis is provided for tomato quality improving and excellent breeding.

This invention provides a process for extracting the flavonoid and alkaloid components from lotus leaf and provides a method for the reduction of body weight, total cholesterol (TC), low density lipoprotein (LDL) cholesterol, and triglycerides (TG). It also provides a method for increasing high density lipoprotein (HDL) cholesterol and the prevention of coronary heart disease (CHD). There are 10% to 80% flavones and 10% to 80% alkaloids in the lotus leaf extract powder of this invention. This process produces an improved standardized raw material that may be utilized as a single dietary supplement, food additive, or medicine and it may be added to other plant extracts, nutraceuticals, or pharmaceuticals.

The invention provides a method for purifying air by using an extract obtained from tea, and the method comprises the following steps of: carrying out granule smashing on tea; placing smashed tea into a soaking tank, and sufficiently soaking by using water; filtering, and remaining soaked tea water and tea residues; placing the tea water into an atomization device; and interacting the tea residues inside an adsorption device and polluted air. The method provided by the invention can be used for removing substances, namely formaldehyde and the like, by using the pure natural substances of the tea by utilizing the principle that active components, namely alkaloid, tea polyphenols, amino acid, and the like which are contained in the tea, can react with the formaldehyde, has the advantages of innocuity on a human body, no secondary pollution generation and obvious effect on formaldehyde removal and can be used for achieving the removal rate of the formaldehyde by 85% within 8 hours in an environment with the formaldehyde of 1 ppm, effectively enhancing the utilization value of the tea and enhancing the development prospect of a tea industry.

The present invention relates to polymeric antitumor agent which is formed in polymeric micelle complex by intermolecular bonding or mutual interaction between styrene maleic acid copolymer (SMA) and low molecule antitumor agent which is anthracyclins drug such as pirarubicin, doxorubicin, epirbicin, daunorbicin, acralbicin, or alkaloid antitumor agent such as cis-platinum, and taxol These polymeric antitumor agents may improve specificity to cancer cells so that it improves antitumor effect, while it may not be concentrated at normal organ or tissue, so that adverse effect may be diminished. These polymeric antitumor agents may be prepared by dissolving SMA and low molecule antitumor agent in aqueous solution, then in the presence of aqueous soluble carbodiimide, amino acids, or polyamine, adjusting pH to form micelle complex and recovering polymer fraction.

An adjuvant composition comprises a Th1-activating alkaloid, optionally further comprising an auxiliary adjuvant selected from a type 2 adjuvant (e.g. alum and / or MF59), a type 1 adjuvant and / or a balanced adjuvant. Vaccines comprising the adjuvant composition include nucleic acid(s) which encode one or more antigenic protein(s); protein(s) or peptide(s); glycoprotein(s); polysaccharide(s) (e.g. carbohydrate(s)); fusion protein(s); lipid(s); glycolipid(s); peptide mimic(s) of polysaccharides carbohydrate(s) and a protein(s) in admixture; carbohydrate-protein conjugate(s); cells or extracts thereof; dead or attenuated cells or extracts thereof; tumour cells or extracts thereof; viral particles (e.g. attenuated viral particles or viral components); allergen(s) mixtures thereof.

Pseudobase benzo[c]phenanthridines and the pharmaceutically acceptable salts thereof of Formula Iare provided herein. The variables R, R1, R2, R3, and R4 are defined herein. Certain pseudobase benzo[c]phenanthridines provided herein act as prodrugs, targeting the parent benzo[c]phenanthridinium alkaloid to hydrophilic or hydrophobic regions in the body. Pharmaceutical compositions comprising a pseudobase benzo[c]phenanthridine and a carrier, excipient, or diluent are provided herein. Methods of treating or preventing microbial, fungal and or viral infections and methods of treating diseases and disorders responsive to protein kinase C modulation, topoisomerase I, and / or topoisomerase II modulation are also provided.

The present invention comprises methods for making compositions derived from Ilex species, particularly Ilex paraguariensis, having lowered caffeine and tannin concentrations, compositions made by such methods, oral delivery formulations, and methods of use of such compositions. In particular, the present invention comprises methods for making maté compositions that have a predetermined characeteristic, such as a lowered amount of caffeine, elevated amounts of caffeoyls, and / or lowered amounts of tannin compounds compared to the native maté plant materials. Further, the invention comprises methods of additional processing steps tp produce compositions having a predetermined alkaloid ratio or profiles to meet particular considerations for final products. The compositions of the present invention may be processed for specific uses such as tablets or other oral delivery vehicles. These compositions may be used in methods for treatment of physiological and medical conditions.

Described herein is a process for removing nicotine and other alkaloids from plant leaf proteins. The plant leaf proteins may be derived from tobacco }Nicotiana tabacum) and other solanaceous and toehr green leaf plants, both non-transgenic and transgenic. The present invention provides efficient techniques for removing nicotine and toehr alkaloids from solanaceous plant-derived leaf proteins to non-detectable levels. Significantly, use of the most preferred method does not substantially reduce leaf protein recovery. Application of these techniques could make leaf proteins derived from solanaceous species suitable for human and animal use consumption.